Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence by Rituximab, Ranimusutine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy

DOI: 10.4236/jct.2013.43A054   PDF   HTML     3,574 Downloads   5,968 Views  

Abstract

The prognosis of CD20-positive (CD20+) diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) recurrence is still poor. A standard treatment for CD20+ DLBCL with CNS recurrence in elderly patients has not been established mainly due to adverse effects. We previously reported the efficacy and safety of MIND-E (ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide) therapy for elderly CD20+ DLBCL patients with CNS recurrence. Here, we report the use of R-MIND-E therapy (rituximab, ranimustine, ifosfamide, procarbazine, dexamethasone and etoposide) in an elderly CD20+ DLBCL patient with CNS recurrence. The patient achieved a complete response according to Revised Response Criteria for Malignant Lymphoma, and treatment-related toxicity was tolerable. R-MIND-E therapy may be a feasible and useful treatment option for elderly CD20+ DLBCL patients with CNS recurrence.

Share and Cite:

J. Miyahara, N. Takezako, M. Wagatsuma, K. Midorikawa, I. Fukuda, S. Noto, I. Saito, K. Yamada, A. Miwa and N. Sekiguchi, "Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence by Rituximab, Ranimusutine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy," Journal of Cancer Therapy, Vol. 4 No. 3A, 2013, pp. 448-451. doi: 10.4236/jct.2013.43A054.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] B. Coiffier, E. Lepage, J. Briere, et al., “CHOP Chemotherapy Plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large B Cell Lymphoma,” New England Journal of Medicine, Vol. 346, No. 4, 2002, pp. 235-242. doi:10.1056/NEJMoa011795
[2] W. M. Tai, J. Chung, P. L. Tang, et al., “Central Nervous System (CNS) Relapse in Diffuse Large B Cell Lymphoma (DLBCL): Preand Post-Rituximab,” Annals of Hematology, Vol. 90, No. 7, 2011, pp. 809-818. doi:10.1007/s00277-010-1150-7
[3] A. Miwa, N. Sekiguchi, A. Tanimura, et al., “Ranimustine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy for Central Nervous System Recurrence of Diffuse Large B-Cell Lymphoma in Patients with Poor Performance Status: A Pilot Study,” Leukemia and Lymphoma, Vol. 52, No. 10, 2011, pp. 1898-1903. doi:10.3109/10428194.2011.588759
[4] G. D. Shah, J. Yahalom, D. D. Correa, et al., “Combined Immunochemotherapy with Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma,” Journal of Clinical Oncology, Vol. 25, No. 30, 2007, pp. 4730-4735. doi:10.1200/JCO.2007.12.5062
[5] R. C. Curry, D. Correa, J. J. Raizer, et al., “Consolidation Reduced Dose Whole Brain Radiotherapy (rdWBRT) Following Methotrexate, Rituximab, Procarbazine, Vincristine, Cytarabine (R-MPV-A) for Newly Diagnosed Primary CNS Lymphoma (PCNSL): Final Results and Long-Term Outcome,” Journal of Clinical Oncology, Vol. 30, No. 15, 2012, p. 2006.
[6] T. Bimbaum, E. A. Stadler, L. V. Baumgarten and A. Straube, “Rituximab Significantly Improves Complete Response Rate in Patients with Primary CNS Lymphoma,” Journal of Neurooncology, Vol. 109, No. 2, 2012, pp. 285-291. doi:10.1007/s11060-012-0891-7
[7] M. J. Wieduwilt, F. Valles, S. Issa, et al., “Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI,” Clincal Cancer Research, Vol. 18, No. 4, 2012, pp. 1146-1155. doi:10.1158/1078-0432.CCR-11-0625
[8] B. D. Cheson, B. Pfistner, M. E. Juweid, et al., “Revised Response Criteria for Malignant Lymphoma,” Journal of Clinical Oncology, Vol. 25, No. 5, 2007, pp. 579-586. doi:10.1200/JCO.2006.09.2403
[9] D. Villa, J. M. Connors, T. N. Shenkier, et al., “Incidence and Risk Factors for Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma: The Impact of the Addition of Rituximab to CHOP Chemotherapy,” Annals of Oncology, Vol. 21, No. 5, 2010, pp. 1046-1052. doi:10.1093/annonc/mdp432
[10] P. Feugier, J. M. Virion, H. Tilly, et al., “Incidence and Risk Factors for Central Nervous System Occurrence in Elderly Patients with Diffuse Large-B-Cell Lymphoma: Influence of Rituximab,” Annals of Oncology, Vol. 15, No. 1, 2004, pp. 129-133. doi:10.1093/annonc/mdh013
[11] Y. Shimizu, K. Notohara, and Y. Ueda, “Diffuse Large B-Cell Lymphoma with Central Nervous System Relapse: Prognosis and Risk Factors According to Retrospective Analysis from a Single-Center Experience,” International Journal of Hematology, Vol. 89, No. 5, 2009, pp. 577-583. doi:10.1007/s12185-009-0289-2
[12] R. Kridel and P. Dietrich, “Prevention of CNS Relapse in Diff Use Large B-Cell Lymphoma,” The Lancet Oncology, Vol. 12, No. 13, 2011, pp. 1258-1266. doi:10.1016/S1470-2045(11)70140-1
[13] A. Harjunpaa, T. Wiklund, J. Collan, et al., “Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma,” Leukemia and Lymphoma, Vol. 42, No. 4, 2001, pp. 731-738. doi:10.3109/10428190109099335
[14] S. J. Kim, S. Y. Oh, J. S. Kim, et al., “Secondary Central Nervous System (CNS) Involvement in Patients with Diffuse Large B-Cell Lymphoma: A Therapeutic Dilemma,” Annals of Hematology, Vol. 90, No. 5, 2011, pp. 539-546. doi:10.1007/s00277-010-1104-0
[15] A. Kumar, A Vanderplas, A. S. LaCasce, et al., “Lack of Benefit of Central Nervous System Prophylaxis for Diffuse Large B-Cell Lymphoma in the Rituximab Era,” Cancer, Vol. 118, No. 11, 2012, pp. 2944-2951. doi:10.1002/cncr.26588
[16] N. Schmitz, S. Zeynalova, M. Loeffler, et al., “Response: Intrathecal Methotrexate and Central Nervous System Events,” Blood, Vol. 114, No. 9, 2009, pp. 1999-2000. doi:10.1182/blood-2009-06-226076
[17] J. S. Abramson, M. Hellmann, J. A. Barnes, et al., “Intravenous Methotrexate as Central Nervous System (CNS) Prophylaxis Is Associated with a Low Risk of CNS Recurrence in High-Risk Patients with Diffuse Large B-Cell Lymphoma,” Cancer, Vol. 116, No. 18, 2010, pp. 4283-4290. doi:10.1002/cncr.25278
[18] Q. A. Hill and R. G. Owen, “CNS Prophylaxis in Lymphoma: Who to Target and What Therapy to Use,” Blood Reviews, Vol. 20, No. 6, 2006, pp. 319-332. doi:10.1016/j.blre.2006.02.001
[19] N. D. Doolittle, L. E. Abrey, T. N. Shenkier, et al., “Brain Parenchyma Involvement as Isolated Central Nervous system Relapse of Systemic Non-Hodgkin Lymphoma an International Primary CNS Lymphoma Collaborative Group Report,” Blood, Vol. 111, No. 3, 2008, pp. 1085-1093. doi:10.1182/blood-2007-07-101402
[20] A. M. P. Omuro, L. M. DeAngelis, Yahalom J, et al., “Chemoradiotherapy for Primary CNS Lymphoma an Intent-to-Treat Analysis with Complete Follow-Up,” Neurology, Vol. 64, No. 1, 2005, pp. 69-74. doi:10.1212/01.WNL.0000148641.98241.5E

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.